Crescent Biopharma to Present at March Investor Conferences
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) will present at two investor conferences in March 2026: TD Cowen on March 2 at 3:50 p.m. ET in Boston and Leerink Partners on March 11 at 8:40 a.m. ET in Miami.
According to Crescent Biopharma, each presentation will be webcast live and replays will be available via the Investors section of the company's website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CBIO
In the Feb 23 session, CBIO declined 1.55%, reflecting a mild negative market reaction. Argus tracked a peak move of +22.4% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | IND clearances | Positive | +0.3% | IND clearances for CR-001 and CR-003 oncology programs with ASCEND plan. |
| Jan 30 | Inducement grants | Neutral | +2.4% | Employee inducement equity option awards under 2025 plan with 10-year term. |
| Feb 05 | Conference appearance | Neutral | -3.1% | Guggenheim biotech summit fireside chat with webcast and 90-day replay. |
| Feb 18 | Clinical trial start | Positive | +4.2% | First patient dosed in ASCEND Phase 1/2 CR-001 trial for solid tumors. |
| Feb 19 | Inducement awards | Positive | +14.2% | Inducement option grants totaling 24,600 shares to non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, particularly clinical progress and corporate actions, has generally seen positive price alignment, including strong upside on routine items like inducement awards.
Over the last few months, Crescent Biopharma has reported multiple milestones. IND clearances for CR-001 and CR-003 on Jan 5, 2026 saw a modest 0.27% gain, while inducement option grants on Jan 30, 2026 coincided with a 2.40% rise. A Guggenheim summit presentation on Feb 5, 2026 preceded a 3.09% decline. Launch of the ASCEND Phase 1/2 trial on Feb 18, 2026 brought a 4.18% increase, and further inducement awards on Feb 19, 2026 saw a strong 14.15% move, underscoring sensitivity to corporate updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:
- TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.
- Leerink Partners 2026 Global Healthcare Conference, fireside chat on Wednesday, March 11, 2026 at 8:40 a.m. ET in Miami.
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
